NEUROIMAGING AND CSF BIOMARKER PROGRAM

FUNDING OPPORTUNITY DESCRIPTION

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a **defined context of use**, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

- developing novel PET ligands for clinical trials

- supporting novel CSF biomarkers

- validating established MRI approaches in larger cohorts

Peripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:

- Neuronal loss

- Vascular injury and blood-brain barrier integrity

- Mitochondria and metabolic function

- Protein misfolding

- Oxidative stress

- White matter changes

- Lewy body dementia

- Other novel targets supported by compelling biological rationale and connection to disease

The ADDF has limited interest in CSF measures of amyloid and tau.

UPCOMING DEADLINES
AWARD INFORMATION
ELIGIBILITY
FUNDING PRIORITIES
EXPECTATIONS AND EVALUATION

APPLICATION SUBMISSIONS

Review the **Application Instructions** for steps on applying.

We encourage you to contact us if you would like to discuss your proposed project and receive initial feedback.

For scientific inquiries, please contact:

Meriel Owen, PhD, Assistant Director, Scientific Affairs

mowen@alzdiscovery.org

For inquiries related to contracting and the online funding portal, please contact:

Grants and Mission-Related Investments Team

grants@alzdiscovery.org

Alzheimer's Drug Discovery
Foundation

57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000

*A GuideStar-Rated
Charity*

© Copyright 2021

Donate
Contact Us
2018 Financials
Careers
Site Map
Terms & Conditions
Privacy Policy